Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients Franck Emmanuel Nicolini , Stéphanie Dulucq , Lisa Boureau , Pascale Cony-Makhoul , Aude Charbonnier , Martine Escoffre-Barbe , Françoise Rigal-Huguet , Valérie Coiteux , Bruno Varet , Viviane Dubruille , Pascal Lenain , Philippe Rousselot , Delphine Rea , Agnès Guerci-Bresler , Laurence Legros , Jixing Liu , Martine Gardembas , Jean-Christophe Ianotto , Pascal Turlure , Hyacinthe Johnson-Ansah , Juliana Martiniuc , Henry Jardel , Bertrand Joly , Patricia Zunic , Tawfiq Henni , Bruno Villemagne , Marc G. Berger , Emilie Cayssials , François Guilhot , Fabrice Larosa , Joëlle Guilhot , Gabriel Etienne , François-Xavier Mahon openalex（2023）
关键词
Treatment Discontinuation
AI 理解论文
溯源树
样例
